This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
The U.S. Food and Drug Administration today approved a risk management program to inform healthcare providers and their patients about the risks of a class of drugs called Erythropoiesis-Stimulating Agents (ESAs). For patients with cancer, the program is also designed to help ensure the appropriate administration of these drugs, which they receive to treat anemia that can occur as a result of chemotherapy.
We care about your feedback. Let us know how we can improve your CancerCompass experience.